 Fauquier ENT News
On December 20, 2024, the U.S. Food and Drug Administration (FDA) has approved Eli Lilly's Zepbound (tirzepatide) as the first medication for treating moderate to severe obstructive sleep apnea (OSA) in adults (older than 18 years) with obesity. OSA is a condition characterized by repeated interruptions in breathing during sleep due to airway obstruction, leading to fragmented sleep and reduced oxygen levels. Traditionally, treatments have included lifestyle changes, continuous positive airway pressure (CPAP) devices, and surgical interventions. The approval of Zepbound introduces a pharmacological option for patients who may not tolerate or benefit from existing therapies. Zepbound is a once-weekly injectable medication that mimics... Read the whole entry... » 
Content mobilized by FeedBlitz RSS Services, the premium FeedBurner alternative. |
